Active substanceChondroitin sulfateChondroitin sulfate
Similar drugsTo uncover
  • Artogistan
    solution w / m 
    GROTEKS, LLC     Russia
  • ARTRA® Chondroitin
    capsules inwards 
    Unipharm, Inc.     USA
  • Arthravir®-Inkamparm®
    solution w / m 
    TRIVIUM-XXI, LLC     Russia
  • Arthradol®
    lyophilizate w / m 
    Inkamfarm, OOO     Russia
  • ARTRADOL®
    capsules inwards 
    TRIVIUM-XXI, LLC     Russia
  • Artrafic
    ointment externally 
    ATOLL, LLC     Russia
  • DRASTOP
    solution w / m 
  • Mukosat®
    solution w / m 
  • Mukosat®
    ointment externally 
       
  • Teraflex® Hondrokrem Forte
    cream externally 
    BAYER, AO     Russia
  • Hondroguard®
    solution w / m 
  • Chondroitin
    capsules inwards 
    VERTEKS, AO     Russia
  • Chondroitin
    gel externally 
    VERTEKS, AO     Russia
  • Chondroitin
    capsules inwards 
    ATOLL, LLC     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
    ELLARA, LTD.     Russia
  • Chondroitin-Akos
    ointment externally 
    SYNTHESIS, OJSC     Russia
  • Chondroitin-Akos
    capsules inwards 
    SYNTHESIS, OJSC     Russia
  • Chondroitin sulfate
    solution w / m 
    Medimeks, ZAO     Russia
  • Chondroitin sulfate
    solution w / m 
    ELLARA, LTD.     Russia
  • Chondroitin sulfate
    lyophilizate w / m 
  • Chondroitin sulfate
    solution w / m 
    BIOSINTEZ, PAO     Russia
  • Chondroxide®
    ointment externally 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Chondroxide®
    gel externally 
    NIZHFARM, JSC     Russia
  • Chondrolon®
    lyophilizate w / m 
  • Dosage form: & nbspsolution for intramuscular injection
    Composition:

    Active substance: chondroitin sodium sulfate 100 mg

    Auxiliary substances: benzyl alcohol 9 mg; water for injection up to 1 ml

    Description:

    Transparent colorless or slightly yellowish liquid with a smell of benzyl alcohol.

    Chondroitin sodium sulfate is an acidic mucopolysaccharide from cartilaginous tracheal tissue of cattle with an average molecular weight of 11 Kdalton.

    Pharmacotherapeutic group:Reparation of tissue stimulant
    ATX: & nbsp

    M.01.A.X.25   Chondroitin sulfate

    Pharmacodynamics:The drug has chondroprotektivnym, stimulating the regeneration of cartilaginous tissue, anti-inflammatory effect. Participates in the construction of the main substance of cartilage and bone tissue, improves phosphoric-calcium metabolism in the cartilaginous tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, inhibits the processes of degeneration of cartilaginous tissue.Stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, promotes the regeneration of cartilaginous surfaces and the articular bag. Warns compression of connective tissue, increases the production of synovial fluid and mobility of affected joints, reduces concomitant inflammation, soreness, helps reduce the need for NSAIDs. With degenerative changes, cartilage tissue is a means of substitution therapy. A positive effect is observed after 2-3 weeks after the start of the drug administration. The therapeutic effect persists for a long time (3-6 months) after the end of the course of treatment.
    Pharmacokinetics:

    Chondroitin sodium sulfate is readily absorbed after intramuscular injection. After 30 minutes it is found in the blood in significant concentrations: the maximum concentration is reached after 1 hour; then its content within 2 days gradually decreases.

    Chondroitin sodium sulfate accumulates mainly in cartilaginous tissue. The synovial membrane is not an obstacle to its penetration into the joint cavity. 15 minutes after intramuscular injection chondroitin sulfate, sodium is found in the synovial fluid, then it enters the articular cartilage, where its content reaches a maximum after 48 hours.

    Indications:Degenerative diseases of the joints and spine: osteoarthritis, intervertebral osteochondrosis.
    Contraindications:Hypersensitivity to the drug, a tendency to bleeding, thrombophlebitis.
    Pregnancy and lactation:Currently, there are no data on the use of Mukosat ® during pregnancy and lactation, and also in children.
    Dosing and Administration:The drug "Mukosat" ® is administered intramuscularly by 1 ml every other day. With good tolerability, the dose is increased to 2 ml, starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, it is possible to conduct repeat courses in 6 months.
    Side effects:Allergic reactions and hemorrhages at the injection site are possible. In these cases, the drug is canceled.
    Interaction:When passing the course of treatment with the drug "Mukosat ®" should be cautious about the simultaneous use of direct anticoagulants. Probably as strengthening of action of not direct anticoagulants, antiplatelet agents and fibrinolytics.
    Form release / dosage:
    Solution for intramuscular injection 100 mg / ml.
    Packaging:

    In the case of production at FBU "GILS and NP":

    1 ml or 2 ml into neutral glass ampoules.

    5 ampoules are placed in a contour mesh box made of a polyvinylchloride film or a polystyrene tape.

    1, 2 or 5 contour squares with instructions for use are placed in a pack of cardboard.

    In the case of production at OJSC Sintez:

    1 ml or 2 ml into neutral glass ampoules or light-protective glass.

    5 ampoules are placed in a contour mesh box made of a polyvinylchloride film and aluminum foil printed lacquered or foil-free.

    1, 2 or 5 contour mesh packages with instructions for use and ampoule ampoule are placed in a pack of cardboard.

    When packing ampoules with a ring of fracture or with a notch and a point, the ampoule scaper is not inserted.

    In the case of production at LLC "Ellara".

    By 1 ml or 2 ml into ampoules of neutral glass or glass with resistance class hydrolysis HGA1 (first hydrolytic).

    By 1 ml or 2 ml in ampoules of light-protective glass or light-protective glass with resistance class hydrolysis HGA1 (first hydrolytic).

    5 ampoules are placed in a contour cell box made of a polyvinylchloride (PVC) film or a polyethylene terephthalate (PET) film.

    1, 2 or 5 contour mesh packages with instructions for use and ampoule ampoule are placed in a pack of cardboard.

    5 or 10 ampoules with instruction for use and ampoule ampoule are placed in a pack of cardboard with a corrugated liner. When packing ampoules with a dot or a ring of fracture, the ampoule scaper is not inserted.

    Storage conditions:List B. Store in a dark place at a temperature of 0 to +20 ° C. Keep out of the reach of children.
    Shelf life:
    3 years. Do not use the drug after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:P N000570 / 01
    Date of registration:09.04.2008 / 02.03.2018
    Expiration Date:Unlimited
    The owner of the registration certificate:FBU "State Institute of Medicines and Good Practices"FBU "State Institute of Medicines and Good Practices"
    Manufacturer: & nbsp
    Information update date: & nbsp20.05.2018
    Illustrated instructions
      Instructions
      Up